Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 2

Status

Terminated 3Completed 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Plasma cell 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 3Urologic Diseases 2Urinary Bladder Diseases 2Carcinoma, Transitional Cell 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Ovarian Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × vofatamab × Clear all
NCT05363605 2023-12-19

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Fusion Pharmaceuticals Inc.

Phase 1/2 Terminated
6 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT03123055 2020-03-18

FIERCE-22

Rainier Therapeutics

Phase 1/2 Terminated
28 enrolled 8 charts
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Diseases

NCT02401542 2020-03-09

FIERCE-21

Rainier Therapeutics

Phase 1/2 Terminated
71 enrolled 9 charts
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Diseases

NCT01122875 2016-11-02

A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Genentech, Inc.

Phase 1 Completed
14 enrolled
Plasma cell

Multiple Myeloma

NCT01363024 2016-11-02

Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors

Genentech, Inc.

Phase 1 Completed
24 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡